Literature DB >> 8919927

Progress in the development of Lactococcus lactis as a recombinant mucosal vaccine delivery system.

P M Norton1, R W Le Page, J M Wells.   

Abstract

The non-pathogenic, non-colonising Gram-positive organism Lactobacillus lactis is beeing developed as an antigen delivery system for mucosal vaccination. A high level expression system has been developed which allows loading of the bacterium with high levels of a heterologous antigen (TTFC) prior to inoculation. Mucosal inoculation of one such recombinant strain results in a protective serum antibody response and production of TTFC-specific IgA at mucosal sites.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8919927     DOI： 10.1007/bf02814197

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN： 0015-5632            Impact factor:   2.099


  7 in total

Review 1.  Targeting and controlled release of antigens for the effective induction of secretory antibody responses.

Authors:  J Mestecky; J H Eldridge
Journal:  Curr Opin Immunol       Date:  1991-08       Impact factor: 7.486

2.  Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis.

Authors:  P M Norton; H W Brown; J M Wells; A M Macpherson; P W Wilson; R W Le Page
Journal:  FEMS Immunol Med Microbiol       Date:  1996-06

3.  Molecular characterization of a cell wall-associated proteinase gene from Streptococcus lactis NCDO763.

Authors:  M Kiwaki; H Ikemura; M Shimizu-Kadota; A Hirashima
Journal:  Mol Microbiol       Date:  1989-03       Impact factor: 3.501

4.  Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge.

Authors:  J M Wells; P W Wilson; P M Norton; M J Gasson; R W Le Page
Journal:  Mol Microbiol       Date:  1993-06       Impact factor: 3.501

5.  A model system for the investigation of heterologous protein secretion pathways in Lactococcus lactis.

Authors:  J M Wells; P W Wilson; P M Norton; R W Le Page
Journal:  Appl Environ Microbiol       Date:  1993-11       Impact factor: 4.792

6.  The immune response to Lactococcus lactis: implications for its use as a vaccine delivery vehicle.

Authors:  P M Norton; H W Brown; R W Le Page
Journal:  FEMS Microbiol Lett       Date:  1994-07-15       Impact factor: 2.742

7.  Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.

Authors:  C K Stover; G P Bansal; M S Hanson; J E Burlein; S R Palaszynski; J F Young; S Koenig; D B Young; A Sadziene; A G Barbour
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307
  7 in total
  4 in total

1.  Receptor binding domain of Escherichia coli F18 fimbrial adhesin FedF can be both efficiently secreted and surface displayed in a functional form in Lactococcus lactis.

Authors:  Agneta Lindholm; Andreas Smeds; Airi Palva
Journal:  Appl Environ Microbiol       Date:  2004-04       Impact factor: 4.792

2.  Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases.

Authors:  Alejandra de Moreno de Leblanc; Silvina Del Carmen; Meritxell Zurita-Turk; Clarissa Santos Rocha; Maarten van de Guchte; Vasco Azevedo; Anderson Miyoshi; Jean Guy Leblanc
Journal:  ISRN Gastroenterol       Date:  2011-02-08

3.  Live bacterial vaccines--a review and identification of potential hazards.

Authors:  Ann Detmer; Jacob Glenting
Journal:  Microb Cell Fact       Date:  2006-06-23       Impact factor: 5.328

Review 4.  Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens.

Authors:  Moloko Gloria Mathipa; Mapitsi Silvester Thantsha
Journal:  Gut Pathog       Date:  2017-05-08       Impact factor: 4.181
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.